Halozyme Therapeutics Inc. (HALO)
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.82 per share a year ago.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology.
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.
Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025
Halozyme Therapeutics, Inc.'s subcu drug delivery business, driven by ENHANZE technology, shows strong revenue growth with significant collaborations, but faces potential challenges post-2030 due to expiring licensing agreements. The failed $2.1bn Evotec acquisition, while initially promising, may have been a blessing in disguise for HALO given Evotec's uncertain and loss-making business model. Recent approvals, including subcutaneous Opdivo (Qvantiq) and other products, e.g. Roche's Ocrevus, suggest a positive outlook for 2025, potentially boosting Halozyme's share price.
Halozyme: Recent Approvals Alter My Appetite
Halozyme's attempt to acquire Evotec was a bold move to diversify revenue but was ultimately unsuccessful, impacting HALO's stock price. Despite a CRL for Rybrevant, Halozyme's technology saw success with FDA approval of Opdivo Qvantig, promising future royalty revenue. Halozyme's strong clinical track record and projected 20% CAGR in royalty revenue position it for significant growth through 2028.
